Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial

INTRODUCTION: The efficacy of natalizumab was evaluated in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) in a 24-week, phase 2 bridging study. An open-label, 2-year extension study from this trial was conducted to assess the safety and efficacy of natalizumab treatment in Japa...

Descripción completa

Detalles Bibliográficos
Autores principales: Saida, Takahiko, Kira, Jun-Ichi, Kishida, Shuji, Yamamura, Takashi, Ohtsuka, Nobuhisa, Ling, Yan, Torii, Shinichi, Lucas, Nisha, Kuesters, Geoffrey, Steiner, Deb, Tibung, J. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447552/
https://www.ncbi.nlm.nih.gov/pubmed/27921221
http://dx.doi.org/10.1007/s40120-016-0059-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447552/
https://www.ncbi.nlm.nih.gov/pubmed/27921221
http://dx.doi.org/10.1007/s40120-016-0059-z

Ejemplares similares